Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn's Disease

  • Boronat-Toscano, Albert|||0000-0003-2650-156X
  • Monfort-Ferré, Diandra|||0000-0003-3832-4249
  • Menacho, Margarita
  • Caro, Aleidis|||0000-0001-6151-3879
  • Bosch Príncep, Ramon|||0000-0003-4104-5515
  • Espina Perez, Beatriz|||0000-0003-1697-9973
  • Algaba, Ferran|||0000-0002-0071-4164
  • Saera-Vila, Alfonso
  • Moliné, Alicia
  • Marti-Gallostra, Marc|||0000-0002-0783-6359
  • Espin-Basany, Eloy|||0000-0002-9139-4548
  • Millán Scheiding, Mónica
  • Serena, Carolina|||0000-0003-2251-0856
Anti-TNF biologics have been shown to markedly improve the quality of life for patients with Crohn's disease (CD), yet one-third of patients fail to benefit from this treatment. Patients with CD develop a characteristic wrapping of visceral adipose tissue (VAT) in the inflamed intestinal area, termed creeping fat, and it is known that adipose tissue expansion influences the efficacy of anti-TNF drugs. We questioned whether anti-TNF therapies impact the creeping fat in CD, which might affect the outcome of the disease. Adipose tissue biopsies were obtained from a cohort of 14 patients with CD that received anti-TNF drugs and from 29 non-anti-TNF-treated patients (control group) matched by sex, age, and body mass index undergoing surgical interventions for symptomatic complications. We found that anti-TNF therapies restored adipose tissue morphology and suppressed immune cell infiltration in the creeping fat. Additionally, anti-TNF treatments appeared to markedly improve the pro-inflammatory phenotype of adipose-tissue macrophages and adipose-tissue-derived stem cells. Our study provides evidence that anti-TNF medications influence immune cells and progenitor cells in the creeping of patients with CD, suppressing inflammation. We propose that perilesional VAT should be considered when administering anti-TNF therapy in patients with CD.